Insider · CIK 0001801050
Howard G. Welgus
Files at ARQT (Arcutis Biotherapeutics, Inc.). First filing Nov 5, 2024, latest Sep 17, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ARQT: Arcutis Biotherapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 3Weak | Arcutis Biotherapeutics, Inc. | $114k 4,730 shares | -12% | - | |
| 6Weak | Arcutis Biotherapeutics, Inc. | $136k 10,139 shares | -8% | +65% from low-21% from high | |
| 21Weak | Arcutis Biotherapeutics, Inc. | $146k 10,000 shares | -8% | +76% from low-15% from high | |
| 21Weak | Arcutis Biotherapeutics, Inc. | $151k 10,000 shares | -8% | +80% from low-13% from high | |
| 21Weak | Arcutis Biotherapeutics, Inc. | $130k 10,000 shares | -7% | - | |
| 21Weak | Arcutis Biotherapeutics, Inc. | $127k 10,000 shares | -7% | - | |
| 21Weak | Arcutis Biotherapeutics, Inc. | $147k 10,000 shares | -6% | - | |
| 21Weak | Arcutis Biotherapeutics, Inc. | $125k 10,000 shares | -6% | - | |
| 19Weak | Arcutis Biotherapeutics, Inc. | $87k 10,000 shares | -5% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | ARQT Arcutis Biotherapeutics, Inc. | MOption exercise Common Stock10b5-1 | +822 | $6.52 | $5,361 | 37,297 | 24 d ago |
| Sep 15, 2026 | ARQT Arcutis Biotherapeutics, Inc. | MOption exercise Common Stock10b5-1 | +1,019 | $7.51 | $7,653 | 38,316 | 24 d ago |
| Sep 15, 2026 | ARQT Arcutis Biotherapeutics, Inc. | MOption exercise Common Stock10b5-1 | +2,255 | $8.63 | $19k | 40,571 | 24 d ago |
| Sep 15, 2026 | ARQT Arcutis Biotherapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,730 | $24.18 | $114k | 35,841 | 24 d ago |
| Sep 15, 2026 | ARQT Arcutis Biotherapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -822 | $0.00 | $0 | 6,574 | 24 d ago |
| Sep 15, 2026 | ARQT Arcutis Biotherapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,019 | $0.00 | $0 | 8,144 | 24 d ago |
| Sep 15, 2026 | ARQT Arcutis Biotherapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,255 | $0.00 | $0 | 18,032 | 24 d ago |
| Jun 18, 2025 | ARQT Arcutis Biotherapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -10,139 | $13.37 | $136k | 109,414 | Jun 20, 2025 |
| Jun 12, 2025 | ARQT Arcutis Biotherapeutics, Inc. | AGrant or award Common Stock | +7,609 | $0.00 | $0 | 119,553 | Jun 16, 2025 |
| Jun 12, 2025 | ARQT Arcutis Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +20,568 | $0.00 | $0 | 20,568 | Jun 16, 2025 |
| May 1, 2025 | ARQT Arcutis Biotherapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -10,000 | $14.64 | $146k | 111,944 | May 5, 2025 |
| Apr 1, 2025 | ARQT Arcutis Biotherapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -10,000 | $15.12 | $151k | 121,944 | Apr 3, 2025 |
| Mar 3, 2025 | ARQT Arcutis Biotherapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -10,000 | $13.00 | $130k | 131,944 | Mar 4, 2025 |
| Feb 3, 2025 | ARQT Arcutis Biotherapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -10,000 | $12.71 | $127k | 141,944 | Feb 4, 2025 |
| Jan 2, 2025 | ARQT Arcutis Biotherapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -10,000 | $14.67 | $147k | 151,944 | Jan 6, 2025 |
| Dec 2, 2024 | ARQT Arcutis Biotherapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -10,000 | $12.51 | $125k | 161,944 | Dec 3, 2024 |
| Nov 1, 2024 | ARQT Arcutis Biotherapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -10,000 | $8.65 | $87k | 171,944 | Nov 5, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.